Well they did their presentation and nhad this news:
InNexus Biotechnology Presents Proof of Principle Data at AACR Annual Meeting 2008
Tuesday April 15, 9:20 am ET
New DXL625 (CD20) Data Demonstrates Superiority Versus Competing CD20 Antibodies
BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB: IXSBF - News)(TSX VENTURE: IXS - News)(http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL™), announced today the company has presented new in vivo proof of principle data at the American Association for Cancer Research (AACR) Annual Meeting 2008 in San Diego, California.
ADVERTISEMENT
“Through the use of a novel in vivo model for B-cell depletion, also developed by InNexus scientists, we have obtained evidence that DXL625 is superior to a competing commercial anti-CD20 in reducing numbers of circulating B-cells. The animal model revealed no increased immunogenicity or toxicity associated with administration of DXL625 versus the commercial anti-CD20,” said Dr. Thomas Kindt, InNexus Biotechnology’s Chief Scientific Officer. “These recent data confirm in vitro results showing DXL625 to be a more potent inducer of B-cell apoptosis and furnish convincing proof of principle demonstrating the superiority of DXL625. The agreement of data from several different types of experimental tests establishes our point concerning the value of DXL™ technology to enhance antibody activity and potency.”
Commenting on the latest achievement of InNexus, Jeff Morhet, Chairman and Chief Executive Officer said, “Establishing this in vivo proof of principle data is another significant milestone in our preclinical development timeline. We’re proud to be presenting this data to our peers at the AACR Annual Meeting 2008 and we will continue to drive forward in our development of DXL625. We are preparing for an upcoming pre-IND meeting with the FDA and our next preclinical milestone is the kickoff of an extensive primate study later this year.”
The data presented at the AACR Annual Meeting 2008 on April 15, 2008 is now available for download at the InNexus website, http://www.ixsbio.com/AACR2008.html.
